Securities code: 603122 securities abbreviation: Hefu China Announcement No.: pro 2022005
Hefu (China) Medical Technology Co., Ltd
Stock trading risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
1. The shares of Hefu (China) Medical Technology Co., Ltd. (hereinafter referred to as “the company”) rose again on March 4, 2022. The company’s price has increased significantly recently. From February 16 to March 4, 2022, it has increased the limit for 12 consecutive trading days (except the first day), and has touched abnormal fluctuations for four times. The company’s stock trading situation has significantly deviated from the growth rate of the same industry and Shanghai Stock exchange index. The company specially reminds investors to pay attention to the trading risks in the secondary market.
2. The P / E ratio of the company is much higher than that of the same industry and comparable listed companies. According to wind data, as of March 4, 2022, the static P / E ratio of the company is 103.69 and the rolling P / E ratio of the company is 105.98. According to the industry data released on the website of China Securities Index Co., Ltd. as of March 4, 2022, the static P / E ratio of the wholesale industry to which the company belongs is 18.93, The rolling P / E ratio is 16.54. Please pay attention to the trading risk. The company has disclosed the announcement of abnormal fluctuations in stock trading for three consecutive times on February 22, February 25 and March 2, 2022, and the announcement of abnormal fluctuations and risks in stock trading on March 4. In view of the fact that the company’s shares have been trading for 12 consecutive trading days (except the first day) from February 16 to March 4, 2022, and the company’s stock price fluctuates greatly in the short term, the company hereby reiterates the following matters and risks. Please make rational decisions and pay attention to investment risks.
1、 Transaction risk prompt of secondary market
As of the date of this announcement, the company’s shares have been trading for 12 consecutive trading days (except the first day), with a cumulative increase of 313.43% in 12 trading days, a cumulative deviation from the Shanghai stock index of 120.35% and a cumulative turnover rate of 69.87%. The company’s short-term share price has increased greatly. Please pay attention to the trading risk of the secondary market, make rational decisions and pay attention to investment risk.
2、 Operation of the company
According to the company’s self inspection, the company’s daily business activities are normal, the market environment and industrial policies have not been significantly adjusted, the production cost and sales have not fluctuated significantly, the internal production and operation order is normal, and the internal and external business environment of the company has not changed significantly.
3、 Relevant risk tips
The company has disclosed the announcement on abnormal fluctuations and risks in stock trading on March 4. In view of the continuous rise and limit of the company’s shares in the short term, the company reiterates the following matters and risks. Please make rational decisions and pay attention to investment risks.
1. Risk of high P / E ratio of the company
The P / E ratio of the company is relatively high. According to wind data, as of March 4, 2022, the static P / E ratio of the company is 103.69 and the rolling P / E ratio of the company is 105.98. According to the industry data released on the website of China Securities Index Co., Ltd. as of March 4, 2022, the static P / E ratio of the wholesale industry of the company is 18.93 and the rolling P / E ratio is 16.54, Investors should pay attention to transaction risks.
As of March 4, 2022, select listed companies close to the company’s main business for price earnings ratio comparison, as follows:
Serial number securities code securities abbreviation static P / E ratio rolling P / E ratio
1 Shanghai Runda Medical Technology Co.Ltd(603108) . SH Shanghai Runda Medical Technology Co.Ltd(603108) 20.97 16.49
Company 103.69 105.98
Note: the data comes from wind
As of March 4, 2022, the company’s rolling P / E ratio is higher than the average value of the above listed companies, while the static P / E ratio is significantly higher than the average value of the above listed companies. Investors should pay attention to transaction risks.
2. Risk of intensified market competition
In recent years, the in vitro diagnosis industry has become one of the rapidly developing fields in China’s medical and health industry. The increasing market demand and the encouragement of national policies will attract more manufacturers to enter, and the market competition will further intensify. If the company cannot continuously improve its product layout, sales and service network in the future, the fierce market competition environment may have an adverse impact on the company’s production, operation and profitability.
3. Epidemic risk of new pneumonia
As the epidemic situation has not yet fundamentally ended, the epidemic prevention work still needs to be continued. In the future, if the New Coronavirus pneumonia epidemic prevention effect in China is not sustainable or affected by COVID-19 pneumonia outside the country, the downstream medical institutions will concentrate on the treatment of COVID-19 pneumonia patients. In order to avoid cross infection in hospitals, the number of regular visits in hospitals will be reduced, which will lead to a reduction in consumption of reagent consumables routinely. May adversely affect the company’s operating performance.
The company solemnly reminds investors that Shanghai Securities News, China Securities News, securities times and Securities Daily are the designated information disclosure newspapers of the company, and the website of Shanghai Stock Exchange (www.sse. Com. CN.) Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please pay attention to investment risks.
It is hereby announced.
Board of directors of Hefu (China) Medical Technology Co., Ltd. March 5, 2022
